子宮肌瘤切除術治療子宮肌瘤的生活質量優於子宮動脈栓塞術
作者:
小柯機器人發布時間:2020/8/1 23:15:05
英國諾丁漢大學Jane P. Daniels團隊比較了子宮肌瘤切除術和子宮動脈栓塞術治療子宮肌瘤的效果。相關論文於2020年7月30日發表在《新英格蘭醫學雜誌》上。
子宮肌瘤是育齡婦女中最常見的一類腫瘤,與月經大出血、腹部不適、不育和生活質量下降有關。對於希望保留子宮且對藥物治療無反應的女性,子宮肌瘤切除術和子宮動脈栓塞術是理想的治療選擇。
研究組進行了一項多中心、隨機、開放標籤試驗,在英國的29家醫院招募了254名患有症狀性子宮肌瘤且不想進行子宮切除術的女性,將其隨機分組,其中127名接受子宮肌瘤切除術,127名接受子宮動脈栓塞術。主要結局是子宮肌瘤相關的生活質量,通過子宮肌瘤症狀和健康相關生活質量問卷(UFS-QOL)進行評分,0-100分,分數越高生活質量越好。
共有206名女性(81%)獲得了主要結局數據。隨訪2年後,在意向治療分析中,子宮肌瘤切除組的UFS-QOL健康相關生活質量得分為84.6±21.5分,顯著高於子宮動脈栓塞組(80.0±22.0分)。子宮肌瘤切除組中29%的女性和子宮動脈栓塞組中24%的女性發生了所有初始手術的圍手術期和術後併發症,無論其是否遵循指定程序。
總之,對於症狀性子宮肌瘤的女性,接受子宮肌瘤切除術2年後的子宮肌瘤相關生活質量優於子宮動脈栓塞術。
附:英文原文
Title: Uterine-Artery Embolization or Myomectomy for Uterine Fibroids
Author: Isaac Manyonda, Ph.D.,, Anna-Maria Belli, F.R.C.R.,, Mary-Ann Lumsden, M.D.,, Jonathan Moss, M.B., Ch.B.,, William McKinnon, Ph.D.,, Lee J. Middleton, M.Sc.,, Versha Cheed, M.Sc.,, Olivia Wu, Ph.D.,, Fusun Sirkeci, M.D.,, Jane P. Daniels, Ph.D.,, and Klim McPherson, Ph.D.
Issue&Volume: 2020-07-29
Abstract: Abstract
Background
Uterine fibroids, the most common type of tumor among women of reproductive age, are associated with heavy menstrual bleeding, abdominal discomfort, subfertility, and a reduced quality of life. For women who wish to preserve their uterus and who have not had a response to medical treatment, myomectomy and uterine-artery embolization are therapeutic options.
Methods
We conducted a multicenter, randomized, open-label trial to evaluate myomectomy, as compared with uterine-artery embolization, in women who had symptomatic uterine fibroids and did not want to undergo hysterectomy. Procedural options included open abdominal, laparoscopic, or hysteroscopic myomectomy. The primary outcome was fibroid-related quality of life, as assessed by the score on the health-related quality-of-life domain of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire (scores range from 0 to 100, with higher scores indicating a better quality of life) at 2 years; adjustment was made for the baseline score.
Results
A total of 254 women, recruited at 29 hospitals in the United Kingdom, were randomly assigned: 127 to the myomectomy group (of whom 105 underwent myomectomy) and 127 to the uterine-artery embolization group (of whom 98 underwent embolization). Data on the primary outcome were available for 206 women (81%). In the intention-to-treat analysis, the mean (±SD) score on the health-related quality-of-life domain of the UFS-QOL questionnaire at 2 years was 84.6±21.5 in the myomectomy group and 80.0±22.0 in the uterine-artery embolization group (mean adjusted difference with complete case analysis, 8.0 points; 95% confidence interval [CI], 1.8 to 14.1; P=0.01; mean adjusted difference with missing responses imputed, 6.5 points; 95% CI, 1.1 to 11.9). Perioperative and postoperative complications from all initial procedures, irrespective of adherence to the assigned procedure, occurred in 29% of the women in the myomectomy group and in 24% of the women in the uterine-artery embolization group.
Conclusions
Among women with symptomatic uterine fibroids, those who underwent myomectomy had a better fibroid-related quality of life at 2 years than those who underwent uterine-artery embolization.
DOI: NJ202007303830511
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1914735